CRISPR Therapeutics (CRSP) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for June 4, 2026, with voting available online and in person.

• Shareholders are asked to approve financial statements, compensation, board elections, and capital structure changes.

Voting matters and shareholder proposals

• Approval of 2025 financial statements and appropriation of results.

• Discharge of Board and Executive Committee members.

• Re-election of all current Board members and Compensation Committee members.

• Binding and advisory votes on compensation for Board and Executive Committee, including maximum amounts and equity.

• Approval of an increase to the capital band and conditional share capital for bond conversions.

• Approval of the 2026 Stock Option and Incentive Plan.

• Re-election of independent voting rights representative and auditors.

• Provision to transact any other business at the meeting.

Board of directors and corporate governance

• All current Board members and Chairman are nominated for re-election.

• Compensation Committee members are also up for re-election.